Dual-Action Antidepressants Effective in Treating Pain With Depression
the Psychiatry Advisor take:
Many patients with depression report having symptoms of pain, even though in many cases, this cannot be explained. However, two classes of antidepressants have been shown to be effective in reducing these symptoms.
Jan Jaracz, MD, PhD, Poznan University of medical Sciences, Poznan, Poland, and colleagues examined 50 patients who participated in a depression study that were diagnosed with moderate or severe depressive episode. The participants were randomized to receive either escitalopram or nortriptyline.
More than 80% of participants in both groups complained of pain at the outset of the trial. However, after two weeks of treatment, patients in both groups said their pain intensity had decreased significantly, the researchers reported in the journal General Hospital Psychiatry.
In addition, improvements in pain also preceded improvement in depression severity. Patients reported a 50% reduction in pain intensity before saying their depression severity was reduced by 50%.
“Both selective serotonergic and noradrenergic antidepressants are equally effective in alleviations of painful physical symptoms of depression,” the researchers concluded.
Widespread Pain Increases Risk of Insomnia
Unexplained painful physical symptoms are commonly reported by depressed patients. The evidence suggests that dual-action antidepressants are potent in relieving pain in depression. However, a direct comparison of the effects of selective serotonergic and selective noradrenergic antidepressants on painful symptoms has not been investigated so far.
Sixty patients who participated in the Genome-based Drugs for Depression (GENDEP) study, with a diagnosis of moderate or severe episodes of depression according to ICD-10 and DSM-IV, criteria were involved.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- FDA Approves Schizophrenia Medication With Digital Ingestion Sensor
- Increased Depression Severity Following Childhood Exposure to Adversity, Risk
- Suboptimal Neuromotor Development Related to Genetic Risk for Schizophrenia
- No Association Between Comorbid Anxiety Disorders, Suicide Attempts
- Cannabidiol Concentration, Labeling Varies Widely in Products Sold Online
- Maintenance rTMS for Treatment-Resistant Depression
- Eye Movement Desensitization and Reprocessing Reduces PTSD Symptoms
- Micronutrients Improve Some Symptoms of ADHD
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- Long-Acting Injectable Antipsychotics Delay Schizophrenia Relapse
- Frequent Migraines Increase Severity of Anxiety, Depression
- Abnormal MRI and CSF Findings May Predict Risk for Alzheimer's Dementia
- Genetic Link Between Obesity Traits, Depression With Atypical Features
- Improved Outcomes for Patients Treated by Own PCP During Hospital Stay
- Patients With Excessive Daytime Sleepiness May Benefit From Sodium Oxybate